Development Services for Next Generation Biopharmaceuticals
Please log in for more information
Paragon Gene Therapy, a unit of Catalent Biologics, provides industry-leading process development and cGMP manufacturing services for next generation biopharmaceuticals such as gene therapies, next-generation vaccines, and oncolytic immunotherapies. Specializing in scalable adeno-associated virus (AAV) platforms across multiple serotypes, Paragon Gene Therapy has several clinical through commercial production facilities in the Greater Maryland area, totalling over 400,000 square feet of space, all in close-proximity to leading universities and government research institutions.
Since 2016, Paragon Gene Therapy has produced more than 100 clinical cGMP batches across 40 programs with many of the leading gene therapy developers worldwide.
Enjoy our FREE content!
Log in or register to gain full unlimited access to all content on the The Medicine Maker site. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.
Catalent Pharma Solutions is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products.
With 85 years’ experience across prescription and consumer markets, Catalent has the deepest expertise, the broadest offerings, and the most innovative technologies, to help its customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and supply.
From a single, tailored solution, to multiple answers throughout a product’s lifecycle, Catalent can improve the total value of treatments, and accelerate programs to clinic and beyond.